Next Article in Journal
In Vitro and In Vivo Anti-Breast Cancer Activities of Some Newly Synthesized 5-(thiophen-2-yl)thieno-[2,3-d]pyrimidin-4-one Candidates
Next Article in Special Issue
Cytotoxic Effects of Diterpenoid Alkaloids Against Human Cancer Cells
Previous Article in Journal
Metabolic Effect of Dietary Taurine Supplementation on Grouper (Epinephelus coioides): A 1H-NMR-Based Metabolomics Study
Previous Article in Special Issue
Antiproliferative Aspidosperma-Type Monoterpenoid Indole Alkaloids from Bousigonia mekongensis Inhibit Tubulin Polymerization
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 12
10.3390/molecules24122254
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Cytotoxicity Evaluation of DOTA-Conjugates of Ursolic Acid

by
Michael Kahnt
1,
Sophie Hoenke
1,
Lucie Fischer
1,
Ahmed Al-Harrasi
2 and
René Csuk
1,*
1
Organic Chemistry, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 2, D-06120 Halle (Saale), Germany
2
Natural and Medical Sciences Research Center, University of Nizwa, PO Box 33, Birkat Al-Mauz, Nizwa 616, Oman
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(12), 2254; https://doi.org/10.3390/molecules24122254
Submission received: 12 May 2019 / Revised: 7 June 2019 / Accepted: 14 June 2019 / Published: 17 June 2019
(This article belongs to the Special Issue Antitumor and Anti-HIV Agents from Natural Products)
Browse Figures
Versions Notes

Abstract

:
In this study, we report the synthesis of several amine-spacered conjugates of ursolic acid (UA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Thus, a total of 11 UA-DOTA conjugates were prepared holding various oligo-methylene diamine spacers as well as different substituents at the acetate units of DOTA including tert-butyl, benzyl, and allyl esters. Furthermore, three synthetic approaches were compared for the ethylenediamine-spacered conjugate 29 regarding reaction steps, yields, and precursor availability. The prepared conjugates were investigated regarding cytotoxicity using SRB assays and a set of human tumor cell lines. The highest cytotoxicity was observed for piperazinyl spacered compound 22. Thereby, EC50 values of 1.5 µM (for A375 melanoma) and 1.7 µM (for A2780 ovarian carcinoma) were determined. Conjugates 22 and 24 were selected for further cytotoxicity investigations including fluorescence microscopy, annexin V assays and cell cycle analysis.

Graphical Abstract

1. Introduction

Despite all medical advances in tumor therapy, cancer is still one of the most prevalent diseases worldwide, with 9.6 million cancer-related deaths counted in 2018 [1]. The research of novel therapeutic approaches and potent chemotherapeutic agents are important contributions in the battle against cancer. However, diagnosis is a prerequisite for successful treatment since an early detection of cancer cells can often significantly reduce the pathogenicity of a tumor and increase the healing rate. One molecule, which made significant impact on the field of diagnostic imaging in the past decades, is the EDTA-related macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA, Figure 1) [2,3].
DOTA-derivatives and complexes thereof are widely used for molecular imaging, especially for the medical diagnosis of cancer [2,3]. By variation of the coordinated metal ion or substituents, they are applicable for a number of imaging techniques, such as magnetic resonance imaging (MRI) [2,3,4], positron emission tomography (PET) [2,3,5,6] and single photon emission computed tomography (SPECT) [2,3,7]. Because of this versatility, a crossover application of DOTA-derivatives as multimodal contrast agents for combined imaging modalities such as PET/MRI or PET/CT is possible and has already been described in the literature [2,3].
Although DOTA and derivatives thereof have a wide range of uses in diagnostic imaging, there are virtually no references for applications in the therapy of cancer. Therefore, we decided to prepare possible cytotoxic DOTA-derivatives by linkage with an ursolic acid backbone. Ursolic acid (UA, Figure 1) is a natural occurring triterpenoic acid with promising pharmacological properties, being widely distributed in various plants and fruits, such as rosemary [8], sage [8], oleander [9], and apples [10,11]. A wide range of biological activities, including antidiabetic, anti-inflammatory, antibacterial, and anticancer effects have been credited to UA and structurally-related derivatives [12,13,14]. Many structural modifications have been described in the literature starting from ursolic acid with various impacts on cytotoxic properties [12,15,16,17,18]. Structure activity investigations concerning modifications at C-3 of UA revealed the presence of an acetyloxy group to be beneficial for obtaining high anti-tumor activity [18]. Furthermore, it has been shown that the modification of C-28 with a piperazine moiety had a positive influence on the cytotoxic properties of ursolic acid [19,20]. Previously, we also have shown oligo-methylene diamine derived carboxamides of ursolic acid to be of high cytotoxicity [21]. Keeping these structure activity relationships in mind, we considered 3-acetyloxy protected and C-28 modified UA derivatives a convenient starting point for the preparation of cytotoxic oligo-methylene diamine spacered DOTA conjugates.

2. Results and Discussion

The synthesis of UA-DOTA conjugates started with the structural modification of cyclen (2) as illustrated in Scheme 1. Treatment of 2 with 3 equiv. of sodium bicarbonate and 3 equiv. of the respective bromoacetic ester (3–5) in dry acetonitrile yielded triple substituted cyclen derivatives 6–8, being ready to be coupled with ursolic acid. We decided to use tert-butyl, benzyl and allyl esters as protecting groups. Benzyl, as well as tert-butyl bromoacetate, were bought from commercial suppliers. Allyl bromoacetate was prepared from allylic alcohol and bromoacetyl bromide.
Ursolic acid has also been modified before coupling with the DOTA precursors (Scheme 2). Derivatization started with the attachment of a spacer moiety using oxalyl chloride and 1-(2-aminoethyl)piperazine in dry dichloromethane affording compound 10. The terminal amino moiety was further substituted with chloroacetyl chloride in dry dichloromethane to furnish the ursolic acid precursor 11 in excellent yield. Linkage of both precursors was performed in dry acetonitrile in the presence of potassium carbonate and potassium iodide yielding UA-DOTA conjugates 12–14. Allylic esters of the acetate groups were removed by treating compound 14 with [(PPh3)4Pd], triphenylphosphane and pyrrolidine in acetonitrile at 25 °C for 3 days; this procedure gave 15 in almost quantitative yield. Purification of 15 was performed by reversed phase chromatography using MeOH/MeCN/TFA as eluent since the compound was difficult to eluate from normal silica phases. Furthermore, a synthetic approach for 15 starting from either 12 or 13 failed. Hydrogenation of 13 employing palladium catalysis retained the benzyl esters, and the deprotection of tert-butyl esters (as in compound 12) using TFA/DCM resulted in a partial degradation of the triterpenoic backbone.
The synthetic approach summarized in Scheme 2 can also be applied to various other spacer units. Thus, we decided to alter the amino component. Therefore, ursolic acid was treated with piperazine, ethylene diamine and 2,2′-oxybis(ethylamine), to furnish ursolic carboxamides 16–18 (Scheme 3), respectively. Chloroacetyl derivatives 19–21 and UA-DOTA conjugates 22–27 were prepared analogous to Scheme 2.
Additionally, an alternative synthetic approach was established for the preparation of the ethylene diamine-spacered UA-DOTA conjugate 29 (Scheme 4). Therefore carboxamide 28 was prepared either by deacetylation of 17 or directly from UA by amidation with ethylene diamine using EDC and HOBt in dry DMF. In the next step, DOTA-tris(tert-butyl ester) (DOTA-3T) was activated by preparing its HOBt ester. Adding 28 to this freshly prepared ester furnished UA-DOTA conjugate 29. For comparison, compound 29 was also synthesized from 24 by removing the C-3 acetyloxy moiety. Due to the presence of an unprotected hydroxyl moiety at this position, compound 29 offers the possibility for a set of modifications and is therefore considered to be a good starting material for further modifications.
Both synthetic approaches for the preparation of 29 (Figure 2) hold advantages but also some disadvantages. Although route A (5 steps) is significantly longer than B, but the former route gave the highest overall yield (44%). Approach B is a rather short and quick way to synthesize 29 (2 steps only), but the overall yield (23%) is barely half as high as in route A. Combining routes A and B, as shown in approach C led to compound 29 in 4 steps with an overall yield of 32%. A major difference between the approaches A and B is the availability and preparation of the DOTA precursors. Both, DOTA-tris(tert-butyl ester) and DO3A-tert-butyl ester (6) are available from commercial suppliers, with DOTA-3T being almost twice as expensive as 6. Most advantageous is the one-step synthesis of 6 starting from cylcen (2), since 2 is commercially available for a price, being almost tenfold lower than that of 6.
Due to cytotoxicity evaluation, the prepared UA-DOTA conjugates were screened in rhodamine B assays employing a series of human tumor cell lines and non-malignant mouse fibroblasts (NIH 3T3). Results of this investigation are summarized in Table 1.
The DO3A-tert-butyl ester (6) showed moderate cytotoxicity as indicated by EC50 values between 10 µM and 14 µM, while DO3A-benzyl ester (7) showed EC50 values lower than 5 µM. Unfortunately, most of the UA-DOTA conjugates were not soluble in solvents suitable for SRB assays. However, combining 7 with ursolic acid gave cytotoxic conjugate 13, showing EC50 values below 6 µM. Removal of ester units (as in 15) resulted in a complete loss of cytotoxicity (EC50 >60 µM for all tumor cells). Compounds 22 and 24, both holding tert-butyl esters but different spacer units were also highly cytotoxic. Piperazine-spacered conjugate 22 showed the highest cytotoxicity observed in this screening for A375 tumor cells (EC50 = 1.5 ± 0.4 µM), while being quite selective, too (SI (NIH 3T3/A375) = 3.07, Table 2). EC50 values of ethylenediamine-spacered conjugate 24 were below 2.5 µM for all tumor cell lines. The highest cytotoxicity was observed for ovarian carcinoma (A2780, EC50 = 1.7 ± 0.1 µM). Removal of the acetyloxy moiety of 24 (as in 29) had almost no significant impact on cytotoxicity.
Because UA-DOTA conjugates 22 and 24 were the most active compounds of this study, these compounds were selected for further cytotoxicity investigations including fluorescence microscopy, annexin V assays, and cell cycle evaluation employing melanoma cells (A375). Microscopic images of A375 cells treated with compound 24 for 24 h showed vital cells (green staining) with some of them having ruptured cell membranes (Figure 3A, white arrows). Further indications of apoptosis have been detected employing flow cytometry and annexin V-FITC/PI staining. After 24 h 63% of the tumor cells treated with 24 were annexin V-FITC-positive, and 51.9% of all cells having died by apoptosis. Additionally, the number of vital cells decreased in comparison to the control from 86.1% to 36.7 % (Figure 3B). An extra investigation of the cell cycle showed a decreased number of cells in G1/G0, G2/M, as well as in S phase. Additionally, a large population of cells has been shifted into the subG1 region (Figure 3C).
Fluorescence microscopic images and density plots of A375 cells treated with 22 for 24 h showed no significant differences in comparison to the control (Supplementary material, Figure S1). Therefore, further investigations were performed with a prolonged incubation time of 48 h. After treating A375 cells with compound 22 for 48 h, subsequent fluorescence microscopic investigations using AO/PI staining showed ruptures of the plasma membrane (Figure 4A, white arrows). Additionally, some necrotic/late stage apoptotic cells were observed, indicated by slightly orange stained nuclei (Figure 4 A, orange arrow). The density plot of A375 cells treated with 22 for 48 h showed a decreased number of vital cells (66.3%) compared to the control (86.0%), while 32.9% of the cells were considered annexin V-FITC-positive. Nearly half of them (17.4% of all cells) have died by apoptosis, and the remaining cells (15.5% of all cells) were secondary necrotic/late stage apoptotic (Figure 4 B). During extra investigations of the cell cycle, some differences compared to the control have been observed. Cells treated with 22 for 48 h showed a quite broad and flat DNA distribution. G1/G0, G2/M, and S phase were drastically reduced, while an increased population of cells with reduced DNA content has been observed in the subG1 region (Figure 4C).

3. Conclusions

In this study, a series of overall 11 amine-spacered UA-DOTA conjugates have been prepared starting from the natural occurring triterpenoid ursolic acid (UA). We hereby report a synthetic approach to UA-DOTA conjugates, which is applicable for several amine spacers and other triterpenoic backbones, too. Additionally, we compared three synthetic approaches for the preparation of compound 29 in terms of yield, number of steps and precursor availability. This conjugate offers the possibility for further modifications at the C-3 hydroxylic group, which is known to influence cytotoxicity. All of the prepared DOTA conjugates were screened in SRB assays showing some compounds to be of good cytotoxicity. EC50 values were determined to range from 17.3 µM to 1.4 µM. The most active compound of this series was a piperazinyl spacered conjugate 22 showing low EC50 values such as 1.5 ± 0.4 µM for A375 tumor cells and 1.9 ± 0.3 µM for A2780 tumor cells, respectively, while showing good selectivity (SI (NIH 3T3(A375) = 3.07), too. Unfortunately, the selectivity of the other screened conjugates was quite low. Additional cytotoxicity investigations such as fluorescence microscopy, annexin V assays, and cell cycle analyses were performed employing the UA-DOTA conjugates 22 and 24 to gain information about their mode of action. The results of these extended biological testing indicate 24 to induce death of A375 cancer cells by apoptosis. These results hold some starting points for further studies. Conjugate 15 and structural related compounds (holding free carboxylic acids at the DOTA unit) are currently subjects of ongoing investigations regarding their ability to form complexes with metal ions or radioactive isotopes like 68Ga to examine possible future uses as tracer or contrast agents in molecular imaging techniques, such as positron emission tomography (PET) [22].

4. Materials and Methods

4.1. General

NMR spectra were recorded using the Varian spectrometers Gemini 2000 or Unity 500 (Varian GmbH, Darmstadt, Germany) δ given in ppm, J in Hz; typical experiments: APT, H-H-COSY, HMBC, HSQC, NOESY), MS spectra were taken on a Finnigan MAT LCQ 7000 (ThermoFisher Scientific, Braunschweig, Germany) electrospray, voltage 4.1 kV, sheath gas nitrogen) instrument. The optical rotations were measured on a Perkin-Elmer polarimeter (Perkin Elmer LAS, Rodgau, Germany) or on a Jasco P-2000 polarimeter (Jasco Germany, Pfungstadt, Germany) at 20 °C; TLC was performed on NP or RP18 silica gel (Macherey-Nagel, detection with cerium molybdate or Dragendorff’s reagent). Melting points are uncorrected (Leica hot stage microscope, or BUCHI melting point M-565), and elemental analyses were performed on a Foss-Heraeus Vario EL (CHNS, Elementar Analysensysteme GmbH, Langenselbold, Germany) unit. IR spectra were recorded on a Perkin Elmer FT-IR spectrometer Spectrum 1000 or on a Perkin-Elmer Spectrum Two (UATR Two Unit; both instruments from Perkin Elmer LAS, Rodgau, Germany). UV-VIS spectra were taken on a Perkin-Elmer Lambda 14 spectrometer or on a Perkin-Elmer Lambda 750 S (UV/VIS/NIR) spectrometer (both instruments from Perkin Elmer LAS, Rodgau, Germany). The solvents were dried according to usual procedures. The purity of the compounds was determined by HPLC and found to be >96%.

4.2. Cytotoxicity

4.2.1. Cell Lines and Culture Conditions

The cell lines used are human cancer cell lines: A2780 (ovarian carcinoma), HT29 (colon adenocarcinoma), MCF-7 (breast adenocarcinoma), A375 (melanoma), FaDu (pharynx squamous cell carcinoma) and non-malignant mouse fibroblasts NIH 3T3; all cell lines were obtained from the Department of Oncology (Martin-Luther-University Halle-Wittenberg). Cultures were maintained as monolayers in RPMI 1640 medium with l-glutamine (Capricorn Scientific GmbH, Ebsdorfergrund, Germany) supplemented with 10% heat inactivated fetal bovine serum (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and penicillin/streptomycin (Capricorn Scientific GmbH, Ebsdorfergrund, Germany) at 37 °C in a humidified atmosphere with 5% CO2.

4.2.2. Cytotoxic Assay (SRB)

The cytotoxicity of the compounds was evaluated using the sulforhodamine-B (Kiton-Red S, ABCR) micro culture colorimetric assay. Cells were seeded into 96-well plates on day 0 at appropriate cell densities to prevent confluence of the cells during the period of experiment. After 24 h, the cells were treated with six different concentrations (1, 3, 7, 12, 20, and 30 µM) minimum. The final concentration of DMSO/DMF never exceeded 0.5%, which was non-toxic to the cells. After a 72-h treatment, the supernatant medium from the 96-well plates was discarded, the cells were fixed with 10% trichloroacetic acid (TCA) and allowed to rest at 4 °C. After 24 h fixation, the cells were washed in a strip washer and dyed with SRB solution (100 µL, 0.4%, in 1% acetic acid) for about 20 min. After dying, the plates were washed four times with 1% acetic acid to remove the excess of the dye and allowed to air-dry overnight. Tris base solution (200 µL, 10 mM) was added to each well and absorbance was measured at λ = 570 nm using a 96 well plate reader (Tecan Spectra, Crailsheim, Germany). The EC50 values were averaged from three independent experiments performed each in triplicate calculated from semi logarithmic dose response curves applying a non-linear 4P Hills-slope equation (GraphPad Prism5; variables top and bottom were set to 100 and 0, respectively).

4.2.3. AO/PI Dye Exclusion Test

Morphological characteristics of cell death were analyzed employing an AO/PI assay using human cancer cell line A375. Approx. 2 × 105 cells were seeded in cell culture flasks (25 cm2), and the cells were allowed to grow up for 24 h. After removing of the used medium, the substance loaded fresh medium was reloaded (or a blank new medium as a control). After 24 h and 48 h, the content of the flask was collected and centrifuged (1200 rpm, 4 °C), the pellet was gently suspended in phosphate-buffered saline (PBS (w/Ca2+ and Mg2+), 1 mL) and centrifuged again. The PBS was removed, and the pellet gently suspended in PBS (150 µL) again. The analysis of the cells was performed using a fluorescence microscope after having mixed the cell suspension (10 µL) with a solution of AO/PI (5 µg/mL, 10 µL).

4.2.4. Annexin V-FITC/PI Assay

Approximately 2 × 105 cells (A375) were seeded in cell culture flasks (25 cm2), and the cells were allowed to grow up for 24 h. After removing of the used medium, the substance loaded fresh medium was reloaded (or a blank fresh medium as a control). After 24 h and 48 h, the cells were harvested, centrifuged (1200 rpm, 4 °C), and washed twice with PBS (w/Ca2+ and Mg2+, 1 mL). The cells were counted and approximately 1∙106 cells were washed with Annexin V binding buffer (BioLegend®, San Diego, USA) and treated with propidium iodide solution (3 µL, 1 mg/mL) and Annexin V-FITC (5 µL, BioLegend®, San Diego, CA, USA) for 15 min in the dark at room temperature. After adding Annexin V binding buffer (400 µL) the suspension was analyzed using Attune® FACS machine. After gating for living cells, the data from detectors BL-1A and BL-3A were collected (20,000 events) in technical triplicates. The assay was performed in duplicates; cell distribution was calculated using Attune® Software (ThermoFisher Scientific, Braunschweig, Germany).

4.2.5. Cell Cycle Investigations

Approximately 2 × 105 cells (A375) were seeded in cell culture flasks (25 cm2), and the cells were allowed to grow up for 24 h. After removing of the used medium, the substance loaded fresh medium was reloaded (or a blank fresh medium as a control). After 24 h or 48 h, respectively, only the adherent cells were harvested, centrifuged (1200 rpm, 4 °C), and washed twice with PBS ((w/w), 1 mL). The cells were counted and approximately 1 × 106 cells were fixed with ethanol (70%, 4 °C, 24 h). After centrifugation (4500 rpm, 4 °C) the cells were washed with PBS ((w/w), 1 mL) and centrifuged. The pellet was resuspended in 1 mL RNAse A containing PI buffer (100µL RNAse (100 mg/mL), 15 µL PI solution (1 mg/mL)) and after incubating for 30 min at room temperature in the dark, cells were analyzed using the Attune® FACS machine; collecting data from the BL-2A channel. Doublet cells were excluded from the measurements by plotting BL-2A against BL-2H. For each cell cycle distribution 20,000 events were collected in technical triplicates, each sample was measured in duplicates. Cell cycle distribution was calculated using ModFitLT™ (Verity Software House, Topsham, ME, USA).

4.3. Syntheses

4.3.1. General

Ursolic acid (1) was obtained from betulinines (Stříbrná Skalice, Czech Republic). 1,4,7,10-Tetraazacyclododecane (cyclen, 2) was bought from abcr GmbH (Karlsruhe, Germany) in 95% purity. Benzyl bromoacetate (96%) and tert-Butyl bromoacetate (98%) were both purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). DOTA-tris(tert-butyl ester) was obtained from TCI Deutschland GmbH (Eschborn, Germany) in 97% purity. Ursolic acid derivatives 10, 16–18 and 28 have been synthesized as previously reported [20,21]. Experimental procedures and full analytical data of these compounds can be found in the supplementary material [23,24].

4.3.2. General Procedure A for the Synthesis of DOTA Precursors (6–8)

To a suspension of cyclen (5.81 mmol) and sodium bicarbonate (17.43 mmol) in dry acetonitrile (100 mL), a solution of the respective bromoacetate (3–5, 17.43 mmol) in dry acetonitrile (10 mL) was added dropwise under argon atmosphere. The mixture was stirred for 48 h at 25 °C. After usual aqueous work-up, the solvent was removed under reduced pressure, and the crude products were subjected to column chromatography (silica gel, chloroform/methanol mixtures) affording DOTA precursors 6–8 (50–68%).

4.3.3. General Procedure B for the Synthesis of Carboxamides (10, 16–18)

Compound 9 (0.5 mmol) was dissolved in dry DCM (10 mL), cooled to 0 °C and oxalyl chloride (3.2 mmol) and dry DMF (2 drops) were added. After warming to 25 °C, the mixture was stirred for 1 h. The solvent was removed under reduced pressure, re-evaporated with dry THF (4 × 15 mL), and the residue was immediately resolved in dry DCM (10 mL). This mixture was then added dropwise to a solution of the amine (3.0 mmol) in dry DCM (2 mL) and stirred at 25 °C for 2 h. After usual aqueous work-up, the solvent was removed under reduced pressure, and the crude products were subjected to column chromatography (silica gel, chloroform/methanol mixtures). Compounds 10 and 16–18 were each obtained as colorless solids (78–82%).

4.3.4. General Procedure C for the Alkylation with Chloroacetyl Chloride (11, 19–21)

Chloroacetyl chloride (2.20 mmol) was added dropwise to a solution of the respective carboxamide (10, 16–18; 1.43 mmol) and triethylamine (0.71 mmol) in dry dichloromethane (75 mL). The mixture was stirred at 25 °C for 0.5–4 h. After usual aqueous work-up, the solvent was removed under reduced pressure, and the crude products were subjected to column chromatography (silica gel, chloroform/acetone mixtures). Compounds 11 and 19–21 were each obtained as colorless solids (91%–94%).

4.3.5. General Procedure D for the Synthesis of Ursolic Acid Chelator Conjugates (12–14, 22–27)

To a solution of the respective chloroacetyl derivative (11, 19–21; 0.44 mmol) and freshly grounded potassium carbonate (0.83 mmol) in dry acetonitrile (15 mL) was added potassium iodide (0.35 mmol) and the respective DOTA precursor (6–8, 0.41 mmol in 5 mL dry acetonitrile). The mixture was stirred for 2–5 days at 25 °C. After completion of the reaction (as indicated by TLC) the mixture was filtered, and the solvent was removed under reduced pressure. The crude products were subjected to column chromatography (silica gel, chloroform/methanol mixtures) to afford compounds 12–14 and 22–27 (yield: 54–88%), respectively.
Allyl bromoacetate (5), To a solution of allyl alcohol (0.62 mol), bromo acetylbromide (0.1 mol) was added dropwise over a period of 30 min at 0 °C under argon atmosphere. The mixture was stirred for 1 h at 0 °C, warmed to 25 °C and stirred for another 3 h. The solvent was removed under reduced pressure and the residue was dissolved in dichloromethane. After usual aqueous work-up, the solvent was removed under reduced pressure, and the crude product was purified by vacuum distillation affording allyl bromoacetate as colorless oil (68%). 1H NMR (400 MHz, CDCl3): δ = 5.88 (ddt, J = 16.5, 11.0, 5.8 Hz, 1H, CH=CH2), 5.38–5.17 (m, 2H, CH=CH2), 4.61 (dt, J = 5.8, 1.4 Hz, 2H, CH2CH=CH2), 3.82 (s, 2H, BrCH2) ppm; 13C NMR (101 MHz, CDCl3): δ = 166.8 (C=O), 131.2 (CH=CH2), 119.0 (CH=CH2), 66.6 (CH2CH=CH2), 25.8 (BrCH2) ppm.
Tri-tert-butyl 2,2′,2’’-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (6), Compound 6 was prepared from 2 according to general procedure A using tert-butyl bromoacetate (3). Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 6 (yield: 50%); m.p. 180–182 °C (lit.: 181–183 °C [25]); Rf = 0.27 (CHCl3/MeOH 95:5); IR (ATR): ν = 2974w, 2943w, 2912w, 2853w, 2736w, 1718s, 1576w, 1466w, 1453w, 1412w, 1392w, 1368m, 1330w, 1255m, 1218w, 1147s, 1117m, 1099m, 1050w, 935m, 873m, 848m cm−1; 1H NMR (400 MHz, CDCl3): δ = 3.36 (s, 4H, 2 × CH2 (acetate)), 3.28 (s, 2H, CH2 (acetate)), 3.12–3.06 (m, 4H, 2 × CH2 (cyclen)), 2.95–2.84 (m, 12H, 6 × CH2 (cyclen)), 1.45 (s, 18H, 6 × CH3 (t-butyl)), 1.45 (s, 9H, 3 × CH3 (t-butyl)) ppm; 13C NMR (101 MHz, CDCl3): δ = 170.6 (2 × CO, acetate), 169.8 (CO, acetate), 81.9 (Cq, t-butyl), 81.8 (2 × Cq, t-butyl), 58.4 (2 × CH2, acetate), 51.5 (2 × CH2, cyclen), 51.4 (2 × CH2, cyclen), 49.4 (2 × CH2, cyclen), 49.0 (CH2, acetate), 47.7 (2 × CH2, cyclen), 28.4 (3 × CH3, t-butyl), 28.3 (6 × CH3, t-butyl) ppm; MS (ESI, MeOH): m/z = 515.3 (100%, [M + H]+), 537.3 (10%, [M + Na]+); analysis calcd for C26H50N4O6 (514.71): C 60.67, H 9.79, N 10.89; found: C 60.51, H 9.98, N 10.67.
Tribenzyl 2,2’,2’’-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (7). Compound 7 was prepared from 2 according to general procedure A using benzyl bromoacetate (4). Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 7 (yield: 68%); Rf = 0.32 (CHCl3/MeOH 95:5); IR (KBr): ν = 2948w, 2857w, 2738w, 1732s, 1586w, 1498w, 1455m, 1418w, 1381w, 1314w, 1169s, 1096m, 1049m, 994m, 739s, 697s cm−1; UV-Vis (CHCl3): λmax (logε) = 251 nm (2.87), 258 nm (2.86), 263 nm (2.76); 1H NMR (400 MHz, CDCl3): δ = 7.40–7.29 (m, 15H, 15 × CH (Bn)), 5.13 (s, 4H, 2 × CH2 (Bn)), 5.13 (s, 2H, CH2 (Bn)), 3.48 (s, 4H, 2 × CH2 (acetate)), 3.41 (s, 2H, CH2 (acetate)), 3.12–3.05 (m, 4H, 2 × CH2 (cyclen)), 2.93–2.79 (m, 12H, 6 × CH2 (cyclen)) ppm; 13C NMR (101 MHz, CDCl3): δ = 171.1 (2 × CO, acetate), 170.3 (CO, acetate), 135.5 (Ci, Bn), 128.8 (CH, Bn), 128.8 (CH, Bn), 128.7 (CH, Bn), 128.7 (CH, Bn), 128.6 (CH, Bn), 66.8 (CH2, Bn), 57.4 (2 × CH2, acetate), 51.9 (2 × CH2, cyclen), 51.7 (2 × CH2, cyclen), 49.6 (2 × CH2, cyclen), 48.8 (CH2, acetate), 47.5 (2 × CH2, cyclen) ppm; MS (ESI, MeOH): m/z = 309.0 (10%, [M + 2H]2+), 617.4 (100%, [M + H]+), 639.3 (10%, [M + Na]+); analysis calcd for C35H44N4O6 (616.76): C 68.16, H 7.19, N 9.08; found: C 67.84, H 7.39, N 8.81.
Triallyl 2,2’,2’’-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (8), Compound 8 was prepared from 2 according to general procedure A using allyl bromoacetate (5). Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 8 (yield: 63%); Rf = 0.27 (CHCl3/MeOH 95:5); IR (KBr): ν = 2945w, 2858w, 2743w, 1731s, 1673w, 1648w, 1455w, 1420w, 1364w, 1314w, 1179s, 1095m, 985s, 928s cm−1; 1H NMR (400 MHz, CDCl3): δ = 5.93–5.81 (m, 3H, 3 × CH (allyl)), 5.32–5.20 (m, 6H, 3 × CH2 (allyl)), 4.60–4.53 (m, 6H, 3 × CH2 (allyl)), 3.49 (s, 4H, 2 × CH2 (acetate)), 3.41 (s, 2H, CH2 (acetate)), 3.12–3.06 (m, 4H, 2 × CH2 (cyclen)), 2.96–2.81 (m, 12H, 6 × CH2 (cyclen)) ppm; 13C NMR (101 MHz, CDCl3): δ = 170.8 (2 × CO, acetate), 170.0 (CO, acetate), 131.7 (2 × CH, allyl), 131.7 (CH, allyl), 119.2 (CH2, allyl), 119.0 (2 × CH2, allyl), 65.5 (2 × CH2, allyl), 65.4 (CH2, allyl), 57.3 (2 × CH2, acetate), 51.7 (2 × CH2, cyclen), 51.6 (2 × CH2, cyclen), 49.4 (2 × CH2, cyclen), 48.5 (CH2, acetate), 47.4 (CH2, cyclen) ppm; MS (ESI, MeOH): m/z = 234.1 (18%, [M + 2H]2+), 467.3 (100%, [M + H]+), 489.3 (10%, [M + Na]+); analysis calcd for C23H38N4O6 (466.6): C 59.21, H 8.21, N 12.01; found: C 59.03, H 8.44, N 11.78.
(3β) 3-Acetyloxy-urs-12-en-28-oic acid (9), Compound 1 was prepared from ursolic acid according to the procedure given in the literature [26]. Yield: 96%; m.p. 287–290 °C (lit.: 289–290 °C [27]).
(3β) N-(2-(4-(2-Chloroacetyl)piperazin-1-yl)ethyl)-3-acetyloxy-urs-12-en-28-amide (11). Compound 11 was synthesized from 10 according to general procedure C. Column chromatography (SiO2, CHCl3/acetone 4:1) furnished compound 11 (91%); m.p. 124–129 °C; [α]D = +32.3° (c 0.320, CHCl3); Rf = 0.38 (CHCl3/acetone 4:1); IR (KBr): ν = 3423s, 2947s, 1734m, 1654s, 1522m, 1458m, 1370m, 1247s, 1150w, 1027m cm−1; 1H NMR (400 MHz, CDCl3): δ = 6.32 (t, J = 5.0 Hz, 1H, NH), 5.28 (t, J = 3.6 Hz, 1H, 12-H), 4.49 (dd, J = 10.4, 5.4 Hz, 1H, 3-H), 4.06 (s, 2H, 36-H), 3.72–3.47 (m, 4H, 34-H, 34′-H), 3.47–3.36 (m, 1H, 31-Ha), 3.25–3.15 (m, 1H, 31-Hb), 2.58–2.39 (m, 6H, 33-H, 32-H, 33′-H), 2.04 (s, 3H, Ac), 2.02–1.80 (m, 5H, 11-Ha, 11-Hb, 16-Ha, 22-Ha, 18-H), 1.79–1.70 (m, 1H, 16-Hb), 1.69–1.21 (m, 13H, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.09 (s, 3H, 27-H), 1.08–1.01 (m, 2H, 1-Hb, 15-Hb), 0.96–0.94 (m, 4H, 20-H, 30-H), 0.93 (s, 3H, 25-H), 0.89–0.86 (m, 3H, 29-H), 0.86 (s, 3H, 23-H), 0.85 (s, 3H, 24-H), 0.84–0.79 (m, 1H, 5-H), 0.78 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.1 (C-28), 171.1 (Ac), 165.2 (C-35), 140.0 (C-13), 125.3 (C-12), 80.9 (C-3), 56.7 (C-32), 55.4 (C-5), 54.2 (C-18), 53.0 (C-33), 52.5 (C-33′), 48.0 (C-17), 47.6 (C-9), 46.5 (C-34), 42.6 (C-14), 42.4 (C-34′), 40.9 (C-36), 39.9 (C-19), 39.7 (C-8), 39.3 (C-20) 38.4 (C-1), 37.8 (C-4), 37.5 (C-22), 37.0 (C-10), 35.9 (C-31), 32.8 (C-7), 31.0 (C-21), 28.2 (C-23), 28.0 (C-15), 25.0 (C-16), 23.6 (C-2), 23.6 (C-11), 23.4 (C-27), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.5 (C-29), 17.1 (C-26), 16.9 (C-24), 15.8 (C-25) ppm; MS (ESI, MeOH): m/z = 686.5 (100%, [M + H]+); analysis calcd for C40H64ClN3O4 (686.42): C 69.99, H 9.40, N 6.12; found: C 69.70, H 9.63, N 6.02.
Tris-t-butyl 2’,2’’-[10-[2-[4-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethyl]piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (12), Compound 12 was synthesized from 6 and 11 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 9:1) furnished compound 12 (54%). m.p. 247–250 °C (decomp.); [α]D = +18.9° (c 0.345, CHCl3); Rf = 0.30 (CHCl3/MeOH 9:1); IR (KBr): ν = 2931m, 1727s, 1644s, 1529w, 1455m, 1425w, 1368s, 1306m, 1228s, 1159s, 1105s, 1005m, 755m cm−1; 1H NMR (400 MHz, CDCl3): δ = 6.38 (s, 1H, NH), 5.26 (t, J = 3.4 Hz, 1H, 12-H), 4.46 (dd, J = 10.5, 5.2 Hz, 1H, 3-H), 3.92–2.04 (m, 36H, 34-H, 34′-H, 36-H, 3 × CH2 (acetate), 31-Ha, 31-Hb, 8 × CH2 (cyclen), 32-H, 33-H, 33′-H), 2.01 (s, 3H, Ac), 2.00–1.68 (m, 4H, 16-Ha, 11-Ha, 11-Hb, 18-H), 1.69–1.14 (m, 14H, 16-Hb, 22-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.42 (s, 27H, 9 × CH3 (t-Butyl)), 1.05 (s, 3H, 27-H), 1.11–0.95 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.91 (d, J = 6.1 Hz, 3H, 30-H), 0.90 (s, 3H, 25-H), 0.85 (d, J = 6.5 Hz, 3H, 29-H), 0.83 (s, 3H, 23-H), 0.82 (s, 3H, 24-H), 0.80–0.75 (m, 1H, 5-H), 0.74 (s, 3H, 26-H) ppm; 13C NMR (100 MHz, CDCl3): δ = 178.0 (C-28), 172.8 (CO, acetate), 171.0 (Ac), 169.8 (C-35), 139.8 (C-13), 125.3 (C-12), 81.9 (Cq, t-Butyl), 81.7 (2 × Cq, t-Butyl), 80.9 (C-3), 56.8 (C-32), 55.8 (3 × CH2, acetate), 55.3 (C-5), 55.2 (C-36), 53.9 (C-18), 53.4 (8 × CH2, cyclen), 52.2 (C-33, C-33′), 47.8 (C-17), 47.5 (C-9), 44.3 (C-34, C-34′), 42.5 (C-14), 39.8 (C-19), 39.7 (C-8), 39.1 (C-20), 38.4 (C-1), 37.8 (C-4), 37.4 (C-22), 36.9 (C-10), 35.7 (C-31), 32.8 (C-7), 31.0 (C-21), 28.2 (C-23), 28.0 (9 × CH3, t-Butyl), 27.9 (C-15), 24.8 (C-16), 23.6 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.4 (C-29), 17.1 (C-26), 16.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 593.9 (100%, [M + Na + H]+), 1186.7 (95%, [M + Na]+); analysis calcd for C66H113N7O10 (1164.67): C 68.06, H 9.78, N 8.42; found: C 67.75, H 9.97, N 8.51.
Tribenzyl 2,2’,2’’-[10-[2-[4-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethyl]piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (13). Compound 13 was synthesized from 7 and 11 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 13 (82%). m.p. 142–146 °C; [α]D = +14.5° (c 0.300, CHCl3); Rf = 0.50 (CHCl3/MeOH 9:1); IR (KBr): ν = 3440s, 2947m, 1734s, 1641s, 1456m, 1371m, 1310w, 1247m, 1197s, 1105m, 1006w, 750m cm−1; UV-Vis (CHCl3): λmax (logε) = 257 nm (3.99); 1H NMR (400 MHz, CDCl3): δ = 7.36–7.24 (m, 15H, CHAr), 6.36–6.28 (m, 1H, NH), 5.27 (t, J = 3.7 Hz, 1H, 12-H), 5.21–5.13 (m, 4H, 2 × CH2Bn), 5.12–5.05 (m, 2H, CH2Bn), 4.47 (dd, J = 10.7, 5.1 Hz, 1H, 3-H), 3.72–2.81 (m, 12H, 34-H, 34′-H, 36-H, 3 × CH2 (acetate)), 3.40–3.30 (m, 1H, 31-Ha), 3.22–3.14 (m, 1H, 31-Hb), 2.46–2.33 (m, 6H, 32-H, 33-H, 33′-H), 2.81–2.06 (m, 16H, 8 × CH2 (cyclen)), 2.03 (s, 3H, Ac), 2.00–1.68 (m, 6H, 16-Ha, 11-Ha, 11-Hb, 18-H, 22-Ha, 16-Hb), 1.68–1.20 (m, 13H, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.06 (s, 3H, 27-H), 1.05–0.94 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.93 (brs, 3H, 30-H), 0.91 (s, 3H, 25-H), 0.85 (d, J = 5.7 Hz, 3H, 29-H), 0.85 (s, 3H, 23-H), 0.83 (s, 3H, 24-H), 0.82–0.77 (m, 1H, 5-H), 0.76 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 177.9 (C-28), 173.5 (CO, acetate), 170.9 (Ac), 170.0 (C-35), 139.7 (C-13), 135.4 (CAr), 135.3 (CAr), 135.2 (CAr), 128.7 (CHAr), 128.6 (CHAr), 128.5 (CHAr), 128.3 (CHAr), 128.3 (CHAr), 128.2 (CHAr), 125.3 (CHAr), 80.8 (C-3), 67.0 (CH2, Bn), 66.8 (CH2, Bn), 56.7 (C-32), 55.4 (C-36), 55.3 (CH2, acetate), 55.2 (C-5), 53.9 (C-18), 53.4 (CH2, cyclen), 52.7 (C-33, C-33′), 47.7 (C-17), 47.4 (C-9), 42.4 (C-14), 39.7 (C-19), 39.5 (C-8), 39.0 (C-20), 38.3 (C-1), 37.6 (C-4), 37.3 (C-22), 36.8 (C-10), 35.8 (C-31), 32.7 (C-7), 30.9 (C-21), 28.0 (C-23), 27.8 (C-15), 24.8 (C-16), 23.5 (C-2), 23.4 (C-11), 23.2 (C-27), 21.3 (Ac), 21.2 (C-30), 18.1 (C-6), 17.3 (C-29), 17.0 (C-26), 16.7 (C-24), 15.6 (C-25) ppm; MS (ESI, MeOH): m/z = 634 (20%, [M + 2H]2+), 645 (100%, [M + H + Na]2+), 1289 (62%, [M + Na]+); analysis calcd for C75H107N7O10 (1266.72): C 71.11, H 8.51, N 7.74; found: C 70.73, H 8.70, N 7.49.
Triallyl 2,2’,2’’-[10-[2-[4-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethyl]piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (14). Compound 14 was synthesized from 8 and 11 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 14 (80%); m.p. 159–163 °C (decomp.); [α]D = +14.8° (c 0.310, CHCl3); Rf = 0.35 (SiO2, CHCl3/MeOH 9:1); IR (KBr): ν = 3342s, 2946m, 2852w, 1734s, 1642s, 1522w, 1456m, 1386w, 1310w, 1246m, 1202m, 1106m, 1026w cm−1; 1H NMR (400 MHz, CDCl3): δ = 6.35 (s, 1H, NH), 5.97 – 5.83 (m, 3H, 3 × CH (allyl)), 5.34–5.19 (m, 7H, 12-H, 3 × CH2 (allyl)), 4.67–4.55 (m, 6H, 3 × CH2 (allyl)), 4.47 (dd, J = 10.6, 5.3 Hz, 1H, 3-H), 3.72–2.97 (m, 14H, 34-H, 34′-H, 36-H, 3 × CH2 (acetate), 31-Ha, 31-Hb), 2.97–2.14 (m, 22H, 8 × CH2 (cyclen), 32-H, 33-H, 33′-H), 2.03 (s, 3H, Ac), 2.01–1.68 (m, 6H, 16-Ha, 11-Ha, 11-Hb, 18-H, 22-Ha, 16-Hb), 1.68–1.19 (m, 13H, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.07 (s, 3H, 27-H), 1.06–0.94 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.94 (d, J = 6.5 Hz, 3H, 30-H), 0.92 (s, 3H, 25-H), 0.87 (d, J = 6.5 Hz, 3H, 29-H), 0.85 (s, 3H, 23-H), 0.83 (s, 3H, 24-H), 0.82–0.78 (m, 1H, 5-H), 0.76 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.0 (C-28), 173.4 (2 x CO, acetate), 173.3 (CO, acetate), 171.1 (Ac), 170.0 (C-35), 139.8 (C-13), 131.9 (2 × CH, allyl), 131.7 (CH, allyl), 125.4 (C-12), 119.0 (CH2, allyl), 118.8 (2 × CH2, allyl), 80.9 (C-3), 66.0 (CH2, allyl), 65.9 (2 × CH2, allyl), 56.8 (C-32), 55.4 (C-36), 55.3 (C-5), 55.2 (3 × CH2, acetate), 53.9 (C-18), 53.6 (8 × CH2, cyclen), 52.7 (C-33, C-33′), 47.9 (C-17), 47.5 (C-9), 45.0 (C-34, C-34′), 42.6 (C-24), 39.8 (C-19), 39.7 (C-8), 39.1 (C-20), 38.4 (C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 35.9 (C-31), 32.8 (C-7), 31.0 (C-21), 28.2 (C-23), 27.9 (C-15), 24.9 (C-16), 23.6 (C-2), 23.6 (C-11), 23.3 (C-27), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.4 (C-29), 17.1 (C-26), 16.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 569.8 (100%, [M + Na + H]+), 1138.8 (52%, [M + Na]+); analysis calcd for C63H101N7O10 (1116.54): C 67.77, H 9.12, N 8.78; found: C 67.50, H 9.37, N 8.43.
2,2’,2’’-[10-[2-[4-[2-(3β-Acetyloxy-urs-12-en-28-oylamino)ethyl]piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid (15). Triphenylphosphane (0.038 mmol), [(PPh3)4Pd] (0.013 mmol) and pyrrolidine (0.290 mmol) were added to a solution of compound 14 (0.128 mmol) in acetonitrile (4 mL), and the mixture was stirred for 6 days at 25 °C. After filtration, the solvent was removed under reduced pressure, and the crude product was subjected to column chromatography (RP18, MeCN/MeOH/TFA 60:40:0.1) affording compound 15 as colorless solid (96%); m.p. 206–210 °C (decomp.); [α]D = +17.1° (c 0.315, MeOH); Rf = 0.35 (RP18, ACN/TFA 100:1); IR (ATR): ν = 2925w, 1634s, 1371m, 1245s, 1199s, 1127s, 1026m, 829m, 800m, 719m cm−1; 1H NMR (400 MHz, CD3OD): δ = 5.35 (t, J = 3.6 Hz, 1H, 12-H), 4.47 (dd, J = 11.0, 5.3 Hz, 1H, 3-H), 3.72–2.93 (m, 14H, 34-H, 34‘-H, 36-H, 31-Ha, 31-Hb, 3 × CH2 (acetate)), 2.91–2.20 (m, 22H, 32-H, 33-H, 33‘-H, 8 × CH2 (cyclen)), 2.09–2.06 (m, 1H, 18-H), 2.03 (s, 3H, Ac), 2.02–1.93 (m, 3H, 11-Ha, 11-Hb, 16-Ha), 1.84–1.23 (m, 15H, 15-Ha, 22-Ha, 1-Ha, 16-Hb, 2-Ha, 2-Hb, 9-H, 7-Ha, 6-Ha, 21-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.15 (s, 3H, 27-H), 1.12–0.96 (m, 3H, 15-Hb, 1-Hb, 20-H), 0.99 (s, 3H, 25-H), 0.97 (brs, 3H, 30-H), 0.92 (d, J = 6.4 Hz, 3H, 29-H), 0.89 (s, 3H, 24-H), 0.88 (s, 3H, 23-H), 0.87–0.84 (m, 1H, 5-H), 0.83 (s, 3H,26-H) ppm; 13C NMR (101 MHz, CD3OD): δ = 180.1 (C-28), 172.8 (Ac), 172.5 (CO, acetate), 172.1 (2 × CO, acetate), 171.2 (C-35), 140.2 (C-13), 127.0 (C-12), 82.4 (C-3), 59.8 (CH2, acetate), 59.7 (CH2, acetate), 59.1 (CH2, acetate), 57.7 (C-32), 56.7 (C-5), 55.3 (C-36), 54.4 (C-18), 54.2 (8 × CH2, cyclen), 53.8 (C-33, C-33‘), 49.0 (C-17), 48.8 (C-9), 46.2 (C-34. C-34‘), 43.4 (C-14), 40.9 (C-8), 40.9 (C-19), 40.3 (C-20), 39.4 (C-1), 38.7 (C-4), 38.7 (C-22), 38.1 (C-10), 37.3 (C-31), 34.0 (C-7), 31.9 (C-21), 29.0 (C-15), 28.6 (C-23), 25.4 (C-16), 24.6 (C-2), 24.5 (C-11), 24.0 (C-27), 21.6 (C-30), 21.1 (Ac), 19.3 (C-6), 18.0 (C-26), 17.8 (C-29), 17.2 (C-24), 16.1 (C-25) ppm; MS (ESI, MeOH, positive ion mode): m/z = 1018.6 (27%, [M + Na]+), 1034.7 (100%, [M + K]+); MS (ESI, MeOH, negative ion mode): m/z = 1017.7 (13%, [M − 2H + Na]–), 1032.6 (100%, [M – 2H + K]–); analysis calcd for C54H89N7O10 (996.35): C 65.10, H 9.00, N 9.84; found: C 64.82, H 9.21, N 9.61.
1-(3β-Acetyloxy-urs-12-en-28-oyl)-4-(2-chloroacetyl) piperazine (19). Compound 19 has been synthesized from 16 according to general procedure C. Column chromatography (SiO2, CHCl3/acetone/hexanes 95:5:20) furnished compound 19 (94%); m.p. 155–158 °C; [α]D = +34.3° (c 0.370, CHCl3); Rf = 0.66 (CHCl3/acetone 9:1); IR (ATR): ν = 2924m, 2871w, 1731m, 1658s, 1455m, 1392m, 1370m, 1243s, 1200m, 1145m, 1025m, 985m, 752m cm−1; 1H NMR (400 MHz, CDCl3): δ = 5.21 (t, J = 3.6 Hz, 1H, 12-H), 4.52–4.45 (m, 1H, 3-H), 4.06 (s, 2H, 34-H), 3.73–3.46 (m, 8H, 31-H, 31′-H, 32-H, 32′-H), 2.41 (d, J = 11.6 Hz, 1H, 18-H), 2.24–2.11 (m, 1H, 16-Ha), 2.03 (s, 3H, Ac), 1.91 (dd, J = 8.9, 3.6 Hz, 2H, 11-Ha, 11-Hb), 1.80–1.24 (m, 15H, 15-Ha, 16-Hb, 22-Ha, 1-Ha, 2-Ha, 2-Hb, 22-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.07 (s, 3H, 27-H), 1.12–0.98 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.95 (d, J = 6.2 Hz, 3H, 30-H), 0.93 (s, 3H, 25-H), 0.88 (d, J = 6.4 Hz, 3H, 29-H), 0.85 (s, 3H, 23-H), 0.84 (s, 3H, 24-H), 0.84–0.77 (m, 1H, 5-H), 0.73 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 175.8 (C-28), 171.1 (Ac), 165.5 (C-33), 138.6 (C-13), 125.5 (C-12), 81.0 (C-3), 55.5 (C-5), 55.1 (C-18), 48.8 (C-17), 47.7 (C-9), 46.3 (C-31), 45.5 (C-31′), 45.1 (C-32), 42.3 (C-32′, C-14), 40.9 (C-34), 39.6 (C-19), 39.6 (C-8), 38.9 (C-20), 38.4 (C-1), 37.8 (C-4), 37.1 (C-10), 34.6 (C-22), 33.1 (C-7), 30.6 (C-21), 28.3 (C-15), 28.2 (C-23), 23.9 (C-27), 23.7 (C-2, C-16), 23.4 (C-11), 21.4 (Ac), 21.4 (C-30), 18.3 (C-6), 17.6 (C-29), 17.0 (C-26), 16.9 (C-24), 15.6 (C-25) ppm; MS (ESI, MeOH): m/z = 643.5 (100%, [M + H]+), 665.4 (56%, [M + Na]+), 1307.3 78%, [2M + Na]+); analysis calcd for C38H59ClN2O4 (643.4): C 70.94, H 9.24, N 4.35; found: C 70.72, H 9.51, N 4.09.
(3β) N-(2-(2-Chloroacetyl)aminoethyl)-3-acetyloxy-urs-12-en-28-amide (20). Compound 20 was synthesized from 17 according to general procedure C. Column chromatography (SiO2, CHCl3/acetone/hexanes 95:5:20) furnished compound 20 (91%); m.p. 103–107 °C; [α]D = +25.2° (c 0.300, CHCl3); Rf = 0.40 (CHCl3/acetone 9:1); IR (KBr): ν = 3422br s, 2948s, 2872m, 1734s, 1640s, 1532s, 1456m, 1370m, 1246s, 1148w, 1092w, 1028m, 756m cm−1; 1H NMR (400 MHz, CDCl3): δ = 7.43 (t, J = 5.1 Hz, 1H, NH), 6.28 (t, J = 5.7 Hz, 1H, NH), 5.32 (t, J = 3.6 Hz, 1H, 12-H), 4.48 (dd, J = 9.7, 6.1 Hz, 1H, 3-H), 4.00 (s, 2H, 34-H), 3.56–3.46 (m, 1H, 31-Ha), 3.41–3.35 (m, 2H, 32-H), 3.26–3.18 (m, 1H, 31-Hb), 2.04 (s, 3H, Ac), 2.03–1.80 (m, 5H, 16-Ha, 11-Ha, 11-Hb, 18-H, 22-Ha), 1.80–1.22 (m, 14H, 16-Hb, 2-Ha, 2-Hb, 1-Ha, 15-Ha, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.08 (s, 3H, 27-H), 1.08–0.95 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.94 (s, 3H, 30-H), 0.93 (s, 3H, 25-H), 0.87 (d, J = 6.5 Hz, 3H, 29-H), 0.86 (s, 3H, 23-H), 0.84 (s, 3H, 24-H), 0.84–0.79 (m, 1H, 5-H), 0.75 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 180.0 (C-28), 171.1 (Ac), 167.0 (C-33), 139.7 (C-13), 125.9 (C-12), 81.0 (C-3), 55.4 (C-5), 53.8 (C-18), 48.0 (C-17), 47.6 (C-9), 42.6 (C-14), 42.6 (C-34), 41.3 (C-32), 39.9 (C-19), 39.7 (C-8), 39.2 (C-31), 39.2 (C-20), 38.4 (C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 32.8 (C-7), 31.0 (C-21), 28.2 (C-23), 27.9 (C-15), 24.9 (C-16), 23.7 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.4 (C-29), 17.0 (C-26), 16.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 617.3 (48%, [M + H]+), 639.5 (52%, [M + Na]+), 1255.4 (100%, [2M + Na]+); analysis calcd for C36H57ClN2O4 (617.31): C 70.04, H 9.31, N 4.54; found: C 69.83, H 9.52, N 4.11.
(3β) N-(2-(2-(2-Chloroacetyl)aminoethoxy)ethyl)-3-acetyloxy-urs-12-en-28-amide (21). Compound 21 has been synthesized from 18 according to general procedure C. Column chromatography (SiO2, CHCl3/acetone/hexanes 95:5:20) furnished compound 21 (91%); m.p. 94–97 °C; [α]D = +33.7° (c 0.335, CHCl3); Rf = 0.35 (CHCl3/acetone 9:1); IR (KBr): ν = 3426br s, 2928m, 2872m, 1734m, 1638s, 1528m, 1458w, 1386w, 1248s, 1124w, 1028m cm−1; 1H NMR (400 MHz, CDCl3): δ = 7.00–6.90 (m, 1H, NH), 6.22 (t, J = 5.0 Hz, 1H, NH), 5.30 (t, J = 3.6 Hz, 1H, 12-H), 4.49 (dd, J = 10.0, 5.7 Hz, 1H, 3-H), 4.06 (s, 2H, 36-H), 3.57–3.47 (m, 7H, 32-H, 31-Ha, 33-H, 34-H), 3.31–3.21 (m, 1H, 31-Hb), 2.04 (s, 3H, Ac), 2.02–1.76 (m, 5H, 16-Ha, 11-Ha, 11-Hb, 18-H, 22-Ha), 1.77–1.21 (m, 14H, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.09 (s, 3H, 27-H), 1.08–0.95 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.94 (d, J = 6.2 Hz, 3H, 30-H), 0.93 (s, 3H, 25-H), 0.88 (d, J = 6.2 Hz, 3H, 29-H), 0.86 (s, 3H, 23-H), 0.85 (s, 3H, 24-H), 0.84–0.80 (m, 1H, 5-H), 0.78 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.4 (C-28), 171.1 (Ac), 166.1 (C-35), 139.9 (C-13), 125.6 (C-12), 80.9 (C-3), 70.0 (C-33), 69.4 (C-32), 55.4 (C-5), 54.0 (C-18), 48.0 (C-17), 47.6 (C-9), 42.8 (C-36), 42.6 (C-14), 39.9 (C-29), 39.8 (C-34), 39.7 (C-8), 39.2 (C-31), 39.2 (C-20), 38.5 (C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 32.8 (C-7), 31.0 (C-21), 28.2 (C-23), 28.0 (C-15), 25.0 (C-16), 23.7 (C-2), 23.6 (C-11), 23.4 (C-27), 21.4 (Ac), 21.4 (C-30), 18.3 (C-6), 17.4 (C-29), 17.1 (C-26), 16.9 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 661.4 (60%, [M + H]+), 685.5 (86%, [M + Na]+), 1343.3 (100%, [2M + Na]+); analysis calcd for C38H61ClN2O5 (661.37): C 69.01, H 9.30, N 4.24, Cl 5.36; found: C 68.80, H 9.61, N 4.01.
Tri-tert-butyl 2,2’,2’’-[10-[2-[4-(3β-acetyloxy-urs-12-en-28-oyl)piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (22). Compound 22 was synthesized from 6 and 19 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 22 (88%); m.p. 237–240 °C (decomp.); [α]D = +15.0° (c 0.3, CHCl3); Rf = 0.42 (CHCl3/MeOH 9:1); IR (ATR): ν = 2927w, 2928w, 2871w, 2829w, 1726s, 1646m, 1453m, 1424w, 1368s, 1305m, 1227s, 1160s, 1105s, 1004m, 975m, 754m cm−1; 1H NMR (400 MHz, CDCl3): δ = 5.19 (t, J = 3.5 Hz, 1H, 12-H), 4.47 (dd, J = 9.8, 6.0 Hz, 1H, 3-H), 3.93–2.05 (m, 32H, 31-H, 31′-H, 32-H, 32′-H, 8 × CH2 (cyclen), 3 × CH2 (acetate), 34-H), 2.40 (d, J = 11.0 Hz, 1H, 18-H), 2.19–2.09 (m, 1H, 16-Ha), 2.02 (s, 3H, Ac), 1.93–1.85 (m, 2H, 11-Ha, 11-Hb), 1.82–1.67 (m, 3H, 15-Ha, 16-Hb, 22-Ha), 1.65–1.21 (m, 12H, 2-Ha, 2-Hb, 22-Hb, 1-Ha, 9-H, 21-Ha, 6-Ha, 7-Ha, 19-H, 21-Hb, 6-Hb, 7-Hb), 1.43 (s, 9H, CH3 (tButyl)), 1.42 (s, 9H; CH3 (tButyl)), 1.42 (s, 9H, CH3 (tButyl)), 1.10–0.96 (m, 3H, 1-Hb, 15-Hb, 20-H), 1.05 (s, 3H, 27-H), 0.92 (d, J = 6.3 Hz, 3H, 30-H), 0.91 (s, 3H, 25-H), 0.86 (d, J = 6.3 Hz, 3H, 29-H), 0.84 (s, 3H, 23-H), 0.82 (s, 3H, 24-H), 0.82–0.76 (m, 1H, 5-H), 0.71 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 175.9 (C-28), 172.8 (CO, acetate), 172.7 (CO, acetate), 171.0 (Ac), 170.7 (C-33), 138.7 (C-13), 125.1 (C-12), 81.9 (Cq, tButyl), 81.7 (Cq, tButyl), 81.7 (Cq, tButyl), 81.0 (C-3), 55.8 (CH2, acetate), 55.8 (CH2, acetate), 55.7 (CH2, cyclen), 55.4 (C-5), 55.1 (C-18), 48.8 (C-17), 47.6 (C-9), 44.6 (C-31, C-31′, C-32, C-32′), 42.3 (C-14), 41.7 (C-34), 39.5 (C-8), 39.4 (C-19), 38.8 (C-20), 38.3 (C-1), 37.8 (C-4), 37.0 (C-10), 34.4 (C-22), 33.1 (C-7), 30.5 (C-21), 28.3 (C-15), 28.2 (C-23), 28.1 (CH3, tButyl), 28.0 (CH3, tButyl), 23.8 (C-27), 23.6 (C-2, C-16), 23.4 (C-11), 21.4 (Ac), 21.3 (C-30), 18.2 (C-6), 17.5 (C-29), 17.0 (C-26), 16.8 (C-24), 15.6 (C-25) ppm; MS (ESI, MeOH): m/z = 1143.7 (100%, [M + Na]+); analysis calcd for C64H108N6O10 (1121.60): C 68.54, H 9.71, N 7.49; found: C 68.31, H 10.03, N 7.27.
Tribenzyl 2,2’,2’’-[10-[2-[4-(3β-acetyloxy-urs-12-en-28-oyl)piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (23). Compound 23 was synthesized from 19 and 7 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 23 (72%); m.p. 157–161 °C; [α]D = +4.2° (c 0.300, CHCl3); Rf = 0.37 (CHCl3/MeOH 9:1); IR (ATR): ν = 2945w, 2836w, 1730s, 1638m, 1454m, 1424w, 1392m, 1370m, 1302m, 1243s, 1194s, 1105s, 1005m, 966m, 743m, 697s cm−1; UV-Vis (CHCl3): λmax (logε) = 246 nm (3.96), 294 nm (3.47), 364 nm (3.23); 1H NMR (400 MHz, CDCl3): δ = 7.39–7.26 (m, 15H, 15 × CH (Bn)), 5.33–4.97 (m, 7H, 12-H, 3 × CH2 (Bn)), 4.45 (dd, J = 10.1, 5.9 Hz, 1H, 3-H), 4.02–2.05 (m, 34H, 31-H, 31‘-H, 32-H, 32‘-H, 8 × CH2 (cyclen), 3 × CH2 (acetate), 34-H, 16-Ha, 18-H), 2.02 (s, 3H, Ac), 1.95–1.65 (m, 5H, 11-Ha, 11-Hb, 15-Ha, 16-Hb, 22-Ha), 1.65–1.09 (m, 12H, 2-Ha, 2-Hb, 22-Hb, 1-Ha, 9-H, 21-Ha, 6-Ha, 7-Ha, 19-H, 21-Hb, 6-Hb, 7-Hb), 1.03 (s, 3H, 27-H), 1.08–0.95 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.93 (d, J = 6.0 Hz, 3H, 30-H), 0.85 (d, J = 6.3 Hz, 3H, 29-H), 0.85 (s, 3H, 25-H), 0.82 (s, 3H, 23-H), 0.79 (s, 3H, 24-H), 0.79–0.71 (m, 1H, 5-H), 0.66 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 175.9 (C-28), 173.6 (CO, acetate), 171.0 (Ac), 170.8 (C-33), 138.6 (C-13), 135.5 (Ci, Bn), 135.3 (Ci, Bn), 128.7 (CH, Bn), 128.7 (CH, Bn), 128.6 (CH, Bn), 128.6 (CH, Bn), 128.4 (CH, Bn), 128.4 (CH, Bn), 125.1 (C-12), 81.0 (C-3), 67.1 (CH2, Bn), 66.9 (CH2, Bn), 55.7 (CH2, acetate), 55.4 (CH2, cyclen), 55.2 (C-5), 55.1 (C-18), 48.7 (C-17), 47.6 (C-9), 44.8 (C-31, C-31‘, C-32, C-32‘), 42.2 (C-14), 42.0 (C-34), 39.5 (C-19), 39.5 (C-8), 38.8 (C-20), 38.3 (C-1), 37.7 (C-4), 36.9 (C-10), 34.5 (C-22), 33.1 (C-7), 30.6 (C-21), 28.2 (C-15), 28.1 (C-23), 23.6 (C-2, C-16), 23.5 (C-27), 23.4 (C-11), 21.4 (Ac), 21.3 (C-30), 18.2 (C-6), 17.5 (C-29), 17.0 (C-26), 16.8 (C-24), 15.5 (C-25) ppm; MS (ESI, MeOH): m/z = 1245.8 (100%, [M + Na]+); analysis calcd for C73H102N6O10 (1223.65): C 71.65, H 8.40, N 6.87; found: C 71.42, H 8.69, N 6.56.
Tri-tert-butyl 2,2’,2’’-[10-[2-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethyl]amino-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (24). Compound 24 was synthesized from 20 and 6 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 24 (73%); m.p. 254–257 °C (decomp.); [α]D = +33.8° (c 0.300, CHCl3); Rf = 0.40 (CHCl3/MeOH 9:1); IR (KBr): ν = 2971m, 2929m, 2829w, 1727s, 1668m, 1520m, 1454m, 1426w, 1368s, 1307m, 1228s, 1159s, 1106s, 1027m, 1006m, 975m, 755m cm−1; 1H NMR (400 MHz, CDCl3): δ = 8.03 (s, 1H, NH), 7.08 (s, 1H, NH), 5.46 (t, J = 3.4 Hz, 1H, 12-H), 4.47 (dd, J = 9.8, 6.1 Hz, 1H, 3-H), 3.80–2.05 (m, 28H, 31-H, 32-H, 34-H, 3 × CH2 (acetate), 8 × CH2 (cyclen)), 2.44–2.38 (m, 1H, 18-H), 2.02 (s, 3H, Ac), 2.00–1.67 (m, 6H, 15-Ha, 11-Ha, 11-Hb, 16-Ha, 16-Hb, 22-Ha), 1.66–1.19 (m, 12H, 1-Ha, 2-Ha, 2-Hb, 22-Hb, 9-H, 6-Ha, 7-Ha, 21-Ha, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.44 (s, 9H, CH3 (tButyl)), 1.43 (s, 9H, CH3 (tButyl)), 1.43 (s, 9H, CH3 (tButyl)), 1.15–0.98 (m, 3H, 20-H, 1-Hb, 15-Hb), 1.04 (s, 3H, 27-H), 0.91 (s, 3H, 25-H), 0.90 (d, J = 6.1 Hz, 3H, 30-H), 0.88 (d, J = 6.1 Hz, 3H, 29-H), 0.84 (s, 3H, 23-H), 0.83 (s, 3H, 24-H), 0.82–0.77 (m, 1H, 5-H), 0.74 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.7 (C-28), 172.4 (CO, acetate), 171.7 (C-33), 171.1 (Ac), 139.0 (C-13), 125.5 (C-12), 82.1 (Cq, tButyl), 82.1 (Cq, tButyl), 82.1 (Cq, tButyl), 81.1 (C-3), 56.4 (3 × CH2, acetate), 55.8 (C-34), 55.8 (CH2, cyclen), 55.4 (C-5), 52.3 (C-18), 47.7 (C-9), 47.6 (C-17), 42.2 (C-14), 40.0 (C-32), 39.7 (C-19), 39.7 (C-8), 38.5 (C-20), 38.4 (C-31, C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 32.9 (C-7), 31.2 (C-21), 28.2 (C-23), 28.2 (CH3, tButyl), 28.1 (CH3, tButyl), 28.1 (CH3, tButyl), 27.9 (C-15), 24.4 (C-16), 23.7 (C-2), 23.5 (C-27), 23.4 (C-11), 21.5 (C-30), 21.4 (Ac), 18.4 (C-6), 17.2 (C-29), 17.0 (C-26), 16.9 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 1117.7 (100%, [M + Na]+); analysis calcd for C62H106N6O10 (1095.56): C 67.97, H 9.75, N 7.67; found: C 67.68, H 10.02, N 7.41.
Tribenzyl 2,2’,2’’-[10-[2-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethyl]amino-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (25). Compound 25 was synthesized from 7 and 20 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 25 (75%); m.p. 142–146 °C; [α]D = +20.5° (c 0.390, CHCl3); Rf = 0.36 (CHCl3/MeOH 9:1); IR (ATR): ν = 2945w, 2832w, 1732s, 1663m, 1519w, 1454m, 1370m, 1305m, 1245s, 1194s, 1176s, 1105s, 1007m, 965m, 747m, 697s cm−1; UV-Vis (CHCl3): λmax (logε) = 241 nm (3.89), 295 nm (3.29), 364 nm (3.08); 1H NMR (400 MHz, CDCl3): δ = 8.20 (t, J = 4.5 Hz, 1H, NH), 7.39–7.27 (m, 15H, CH (Bn)), 7.01 (t, J = 4.9 Hz, 1H, NH), 5.48 (s, 1H, 12-H), 5.26–5.05 (m, 6H, CH2 (Bn)), 4.47 (dd, J = 10.0, 5.7 Hz, 1H, 3-H), 3.77–2.07 (m, 28H, 31-Ha, 31-Hb, 32-H, 34-H, 3 × CH2 (acetate), 8 × CH2 (cyclen)), 2.41 (d, J = 10.7 Hz, 1H, 18-H), 2.02 (s, 3H, Ac), 2.00–1.64 (m, 6H, 16-Ha, 16-Hb, 11-Ha, 11-Hb, 22-Ha, 15-Ha), 1.64–1.19 (m, 12H, 1-Ha, 2-Ha, 2-Hb, 22-Hb, 9-H, 6-Ha, 7-Ha, 21-Ha, 6-Hb, 19-H, 21-Hb, 7-Hb), 1.17–0.97 (m, 3H, 20-H, 1-Hb, 15-Hb), 1.04 (s, 3H, 27-H), 0.89 (d, J = 6.3 Hz, 6H, 29-H, 30-H), 0.87 (s, 3H, 25-H), 0.83 (s, 3H, 23-H), 0.81 (s, 3H, 24-H), 0.80–0.76 (m, 1H, 5-H), 0.72 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.8 (C-28), 173.2 (CO, acetate), 172.0 (C-33), 171.0 (Ac), 139.0 (C-13), 135.4 (Ci, Bn), 135.4 (Ci, Bn), 135.3 (Ci, Bn), 128.8 (CH, Bn), 128.8 (CH, Bn), 128.7 (CH, Bn), 128.6 (CH, Bn), 125.6 (12-H), 81.0 (3-H), 67.3 (CH2, Bn), 67.3 (CH2, Bn), 67.2 (CH2, Bn), 56.8 (CH2, acetate), 55.4 (C-34), 55.3 (C-5), 55.3 (CH2, cyclen), 52.3 (C-18), 47.7 (C-17), 47.6 (C-9), 42.2 (C-14), 40.1 (C-32), 39.8 (C-19), 39.7 (C-8), 38.5 (C-20), 38.5 (C-31, C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 32.9 (C-7), 31.2 (C-21), 28.2 (C-23), 28.0 (C-15), 24.5 (C-16), 23.7 (C-2), 23.5 (C-27), 23.4 (C-11), 21.4 (Ac), 21.4 (C-30), 18.4 (C-6), 17.2 (C-29), 17.1 (C-26), 16.8 (C-24), 15.6 (C-25) ppm; MS (ESI, MeOH): m/z = 1219.8 (100%, [M + Na]+); analysis calcd for C71H100N6O10 (1197.61): C 71.21, H 8.42, N 7.02; found: 70.93, H 8.56, N 6.82.
Tri-tert-butyl 2,2’,2’’-[10-[2-[2-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethoxy]ethyl]amino-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (26). Compound 26 was synthesized from 6 and 21 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 26 (74%); m.p. 263–266 °C (decomp.); [α]D = +21.9° (c 0.315, CHCl3); Rf = 0.38 (CHCl3/MeOH 9:1); IR (ATR): ν = 2972m, 2930m, 1726s, 1166m, 1523w, 1453m, 1368s, 1307m, 1228s, 1160s, 1106s, 1026m, 1006m, 975m, 755m cm−1; 1H NMR (400 MHz, CDCl3): δ = 7.82 (t, J = 5.6 Hz, 1H, NH), 6.46 (t, J = 5.1 Hz, 1H, NH), 5.33 (t, J = 3.7 Hz, 1H, 12-H), 4.47 (dd, J = 10.2, 5.9 Hz, 1H, 3-H), 3.56–3.30 (m, 9H, 32-H, 31-Ha, 33-H, 36-H, 34-H), 3.28–3.16 (m, 1H, 31-Hb), 3.15–2.05 (m, 22H, 3 × CH2 (acetate), 8 × CH2 (cyclen)), 2.02 (s, 3H, Ac), 2.02–1.21 (m, 19H, 18-H, 16-Ha, 11-Ha, 11-Hb, 22-Hb, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.44 (s, 9H, CH3 (tButyl)), 1.43 (s, 18H, CH3 (tButyl)), 1.06 (s, 3H, 27-H), 1.05–0.94 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.92 (s, 3H, 25-H), 0.92 (d, J = 6.2 Hz, 3H, 30-H), 0.86 (d, J = 6.5 Hz, 3H, 29-H), 0.84 (s, 3H, 23-H), 0.83 (s, 3H, 24-H), 0.82–0.77 (m, 1H, 5-H), 0.76 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.3 (C-28), 173.0 (CO, acetate), 172.5 (CO, acetate), 172.1 (C-35), 171.1 (Ac), 139.3 (C-13), 125.7 (C-12), 82.1 (Cq, tButyl), 82.0 (Cq, tButyl), 81.9 (Cq, tButyl), 81.0 (C-3), 69.5 (C-33), 69.0 (C-32), 56.5 (C-36), 55.9 (CH2, acetate), 55.8 (CH2, acetate), 55.7 (CH2, cyclen), 55.4 (C-5), 53.4 (C-18), 47.8 (C-17), 47.6 (C-9), 42.4 (C-14), 39.8 (C-19), 39.7 (C-8), 39.2 (C-31), 39.0 (C-34), 39.0 (C-20), 38.4 (C-1), 37.8 (C-4), 37.3 (C-22), 37.0 (C-10), 32.9 (C-7), 31.1 (C-21), 28.2 (CH3, tButyl), 28.0 (CH3, tButyl), 28.0 (C-23), 28.0 (C-15), 24.9 (C-16), 23.7 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (Ac), 21.4 (C-30), 18.3 (C-6), 17.3 (C-29), 17.0 (C-26), 16.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 1161.7 (100%, [M + Na]+); analysis calcd for C64H110N6O11 (1139.6): C 67.45, H 9.73, N 7.37; found: C 67.31, H 9.87, N 7.09.
Tribenzyl 2,2’,2’’-[10-[2-[2-[2-(3β-acetyloxy-urs-12-en-28-oylamino)ethoxy]ethyl]amino-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (27). Compound 27 has been synthesized from 7 and 21 according to general procedure D. Column chromatography (SiO2, CHCl3/MeOH 95:5) furnished compound 27 (62%); m.p. 137–141 °C; [α]D = +15.4° (c 0.350, CHCl3); Rf = 0.35 (CHCl3/MeOH 9:1); IR (ATR): ν = 2945w, 2830w, 1731s, 1662m, 1523w, 1454m, 1390m, 1370m, 1305m, 1245s, 1193s, 1105s, 1026m, 1008m, 967m, 747m, 697m cm−1; UV-Vis (CHCl3): λmax (logε) = 244 nm (3.73), 294 nm (3.36), 363 nm (3.12); 1H NMR (400 MHz, CDCl3): δ = 8.02 (t, J = 5.4 Hz, 1H, NH), 7.37–7.27 (m, 15H, CH (Bn)), 6.48 (t, J = 5.1 Hz, 1H, NH), 5.32 (t, J = 3.5 Hz, 1H, 12-H), 5.24–5.14 (m, 4H, CH2 (Bn)), 5.14–5.05 (m, 2H, CH2 (Bn)), 4.46 (dd, J = 10.2, 5.7 Hz, 1H, 3-H), 3.59–3.33 (m, 9H, 32-H, 33-H, 31-Ha, 34-H, 36-H), 3.33–2.01 (m, 23H, 31-Hb, 8 × CH2 (cyclen), 3 × CH2 (acetate)), 2.02 (s, 3H, Ac), 2.00–1.17 (m, 19H, 18-H, 16-Ha, 11-Ha, 11-Hb, 22-Ha, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 22-Hb, 7-Ha, 21-Ha, 19-H, 6-Hb, 7-Hb, 21-Hb), 1.05 (s, 3H, 27-H), 1.04 – 0.94 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.90 (s, 3H, 25-H), 0.90 (d, J = 5.8 Hz, 3H, 30-H), 0.85 (d, J = 6.6 Hz, 3H, 29-H), 0.84 (s, 3H, 23-H), 0.82 (s, 3H, 24-H), 0.81–0.76 (m, 1H, 5-H), 0.75 (s, 3H, 26-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.3 (C-28), 173.3 (CO, acetate), 173.1 (CO, acetate), 172.3 (C-35), 171.1 (Ac), 139.3 (C-13), 135.4 (Ci, Bn), 135.3 (Ci, Bn), 128.7 (CH, Bn), 128.7 (CH, Bn), 128.7 (CH, Bn), 128.6 (CH, Bn), 128.5 (CH, Bn), 125.7 (C-12), 81.0 (C-3), 69.6 (C-33), 68.9 (C-32), 67.2 (CH2, Bn), 67.2 (CH2, Bn), 56.9 (C-36), 55.4 (3 × CH2, acetate), 55.4 (C-5), 55.3 (8 × CH2, cyclen), 53.3 (C-18), 47.8 (C-17), 47.6 (C-9), 42.4 (C-14), 39.8 (C-19), 39.7 (C-8), 39.2 (C-31, C-34), 38.9 (C-20), 38.4 (C-1), 37.8 (C-4), 37.3 (C-22), 36.9 (C-10), 32.9 (C-7), 31.1 (C-21), 28.2 (C-23), 28.0 (C-15), 24.8 (C-16), 23.6 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (Ac), 21.4 (C-30), 18.3 (C-6), 17.3 (C-29), 17.1 (C-26), 16.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 1263.9 (100%, [M + Na]+); analysis calcd for C73H104N6O11 (1241.67): C 70.62, H 8.44, N 6.77; found: C 70.41, H 8.69, N 6.41.
(3β) N-(2-Aminoethyl)-3-hydroxy-urs-12-en-28-amide (28). Method A: The synthesis was performed according to the procedure given in the Supplementary material in 82%. Method B: Ursolic acid (100 mg, 0.20 mmol), HOBt·H2O (37 mg, 0.24 mmol) and EDC·HCl (46 mg, 0.24 mmol) were dissolved in dry DMF (5 mL), and the mixture was stirred for 30 min at 25 °C. Ethylene diamine (55 µL, 0.82 mmol) was added to the mixture, and stirring was continued for 24 h at 25 °C. Usual aqueous work-up followed by column chromatography (silica gel, CHCl3/MeOH/NH4OH 90:10:0.1) gave 28 (46%). Analytical data of this compound can be found in the supplementary material.
Tri-tert-butyl 2,2’,2’’-[10-[2-[2-(3β-hydroxy-urs-12-en-28-oylamino)ethyl]amino-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (29). Method A: To a solution of DOTA-tris(tert-butyl ester) (58 mg, 0.10 mmol) in dry DMF (8 mL) were added HOBt·H2O (29 mg, 0.19 mmol) and EDC·HCl (29 mg, 0.15 mmol). After stirring for 30 min at 25 °C, a solution of 28 (71 mg, 0.14 mmol) in dry DMF (2 mL) was added and stirring was continued for 5 days. After usual aqueous work-up, the solvent was removed under reduced pressure and the crude product was subjected to column chromatography (silica gel, CHCl3/MeOH 9:1) yielding compound 29 as colorless solid. Yield: 49%. Method B: Compound 24 (50 mg, 0.10 mmol) was dissolved in methanol (7 mL) and a solution of potassium hydroxide (12 mg, 0.21 mmol) in methanol (1 mL) was added. The mixture was stirred at 25 °C for 24 h. After completion of the reaction (as indicated by TLC) and usual work-up, the solvent was removed under reduced pressure, and the residue was subjected to column chromatography (silica gel, CHCl3/MeOH 9:1) affording 29 (yield: 86%); m.p. 136–139 °C; [α]D = −44.4° (c 0.330, MeOH); Rf = 0.29 (CHCl3/MeOH 9:1); IR (KBr): ν = 3300br w, 2973w, 2928m, 2869w, 1728s, 1668m, 1525m, 1455m, 1425w, 1368s, 1307m, 1227s, 1159s, 1121m, 1106s, 1047w, 1006w cm−1; 1H NMR (400 MHz, CDCl3): δ = 8.84 (s, 1H, NH), 7.55 (s, 1H, NH), 5.36 (t, J = 3.5 Hz, 1H, 12-H), 3.59–2.05 (m, 28H, 31-H, 32-H, 33-H, 3 × CH2 (acetate), 8 × CH2 (cyclen)), 3.20 (dd, J = 11.1, 4.8 Hz, 1H, 3-H), 2.34 (d, J = 11.0 Hz, 2H, 18-H), 2.03–1.96 (m, 1H, 16-Ha), 1.95–1.83 (m, 3H, 11-Ha, 11-Hb, 16-Hb), 1.83–1.72 (m, 1H, 22-Ha), 1.64–1.21 (m, 13H, 1-Ha, 15-Ha, 2-Ha, 2-Hb, 22-Hb, 6-Ha, 9-H, 7-Ha, 21-Ha, 19-H, 6-Hb, 7-Hb, 21-Hb), 1.45 (s, 9H, CH3 (tButyl)), 1.43 (s, 18H, CH3 (tButyl)), 1.05 (s, 3H, 27-H), 1.04–0.97 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.97 (s, 3H, 23-H), 0.89 (d, J = 6.3 Hz, 3H, 30-H), 0.89 (s, 3H, 25-H), 0.85 (d, J = 6.4 Hz, 3H, 29-H), 0.76 (s, 3H, 24-H), 0.75 (s, 3H, 26-H), 0.72–0.68 (m, 1H, 5-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 178.4 (C-28), 172.4 (CO, acetate), 171.8 (C-33), 138.9 (C-13), 125.3 (C-12), 82.2 (Cq, tButyl), 82.1 (Cq, tButyl), 82.1 (Cq, tButyl), 79.2 (C-3), 56.0 (CH2, acetate), 55.9 (C-34), 55.8 (CH2, cyclen), 55.3 (C-5), 52.5 (C-18), 47.8 (C-9), 47.5 (C-17), 42.2 (C-14), 40.0 (C-32), 39.7 (C-8), 39.6 (C-19), 38.9 (C-4), 38.7 (C-20), 38.7 (C-31, C-1), 37.4 (C-22), 37.1 (C-10), 33.2 (C-7), 31.3 (C-21), 28.3 (C-23), 28.2 (CH3, tButyl), 28.2 (CH3, tButyl), 28.1 (CH3, tButyl), 28.0 (C-15), 27.4 (C-2), 24.2 (C-16), 23.6 (C-27), 23.5 (C-11), 21.5 (C-30), 18.6 (C-6), 17.2 (C-29), 17.1 (C-26), 15.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 1075.7 (100%, [M + Na]+); analysis calcd for C60H104N6O9 (1053.53): C 68.40, H 9.95, N 7.98; found: C 60.09, H 10.11, N 7.83.

Supplementary Materials

Supplementary data related to this article including experimental procedures for compounds 10, 17, 18, and 28, Figure S1: Extended cytotoxicity investigation after treatment of A375 cells with 22 (3.0 µM) for 24 h, representative NMR spectra and calculation of ADMET parameters for compounds 22 and 24 can be found online.

Author Contributions

M.K.; and R.C. conceived and designed the experiments; M.K. performed the experiments; S.H. and L.F. performed the biological assays and experiments; M.K.; A.A-H.; and R.C. analyzed the data and wrote the paper.

Funding

We acknowledge the financial support within the funding program Open Access Publishing by the German Research Foundation (DFG).

Acknowledgments

We would like to thank R. Kluge for measuring the ESI-MS spectra and D. Ströhl and his team for the NMR spectra. Thanks are also due to V. Simon for measuring the IR an UV-VIS spectra and optical rotations. The cell lines were kindly provided by Th. Müller (Dept. of Haematology/Oncology, Martin-Luther Universität Halle-Wittenberg).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Stasiuk, G.J.; Long, N.J. The ubiquitous DOTA and its derivatives: The impact of 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid on biomedical imaging. Chem. Commun. 2013, 49, 2732–2746. [Google Scholar] [CrossRef] [PubMed]
  3. Chilla, S.N.M.; Henoumont, C.; Elst, L.V.; Muller, R.N.; Laurent, S. Importance of DOTA derivatives in bimodal imaging. Isr. J. Chem. 2017, 57, 800–808. [Google Scholar] [CrossRef] [Green Version]
  4. Magerstädt, M.; Gansow, O.A.; Brechbiel, M.W.; Colcher, D.; Baltzer, L.; Knop, R.H.; Girton, M.E.; Naegele, M. Gd (DOTA): An alternative to Gd (DTPA) as a T1, 2 relaxation agent for NMR imaging or spectroscopy. Magn. Reson. Med. 1986, 3, 808–812. [Google Scholar] [CrossRef] [PubMed]
  5. Jones-Wilson, T.M.; Deal, K.A.; Anderson, C.J.; McCarthy, D.W.; Kovacs, Z.; Motekaitis, R.J.; Sherry, A.D.; Martell, A.E.; Welch, M.J. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl. Med. Biol. 1998, 25, 523–530. [Google Scholar] [CrossRef]
  6. Wu, A.M.; Yazaki, P.J.; Tsai, S.-w.; Nguyen, K.; Anderson, A.-L.; McCarthy, D.W.; Welch, M.J.; Shively, J.E.; Williams, L.E.; Raubitschek, A.A. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. USA 2000, 97, 8495–8500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Deshpande, S.V.; DeNardo, S.J.; Kukis, D.L.; Moi, M.K.; McCall, M.J.; DeNardo, G.L.; Meares, C.F. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med. 1990, 31, 473–479. [Google Scholar]
  8. Razboršek, M.I.; Vončina, D.B.; Doleček, V.; Vončina, E. Determination of Oleanolic, Betulinic and Ursolic Acid in Lamiaceae and Mass Spectral Fragmentation of Their Trimethylsilylated Derivatives. Chromatographia 2008, 67, 433–440. [Google Scholar] [CrossRef]
  9. Fu, L.; Zhang, S.; Li, N.; Wang, J.; Zhao, M.; Sakai, J.; Hasegawa, T.; Mitsui, T.; Kataoka, T.; Oka, S.; et al. Three New Triterpenes from Nerium oleander and Biological Activity of the Isolated Compounds. J. Nat. Prod. 2005, 68, 198–206. [Google Scholar] [CrossRef]
  10. Cargnin, S.T.; Gnoatto, S.B. Ursolic acid from apple pomace and traditional plants: A valuable triterpenoid with functional properties. Food Chem. 2017, 220, 477–489. [Google Scholar] [CrossRef]
  11. Yamaguchi, H.; Noshita, T.; Kidachi, Y.; Umetsu, H.; Hayashi, M.; Komiyama, K.; Funayama, S.; Ryoyama, K. Isolation of Ursolic Acid from Apple Peels and Its Specific Efficacy as a Potent Antitumor Agent. J. Health Sci. 2008, 54, 654–660. [Google Scholar] [CrossRef] [Green Version]
  12. Chen, H.; Gao, Y.; Wang, A.; Zhou, X.; Zheng, Y.; Zhou, J. Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents. Eur. J. Med. Chem. 2015, 92, 648–655. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Hussain, H.; Green, I.R.; Ali, I.; Khan, I.A.; Ali, Z.; Al-Sadi, A.M.; Ahmed, I. Ursolic acid derivatives for pharmaceutical use: A patent review (2012-2016). Expert Opin. Pat. 2017, 27, 1061–1072. [Google Scholar] [CrossRef] [PubMed]
  14. Seo, D.Y.; Lee, S.R.; Heo, J.-W.; No, M.-H.; Rhee, B.D.; Ko, K.S.; Kwak, H.-B.; Han, J. Ursolic acid in health and disease. Korean J. Physiol. Pharm. 2018, 22, 235–248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Zou, J.; Lin, J.; Li, C.; Zhao, R.; Fan, L.; Yu, J.; Shao, J. Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies. Curr. Cancer Drug Targets 2019, 19, 245–256. [Google Scholar] [CrossRef] [PubMed]
  16. Ma, C.-M.; Cai, S.-Q.; Cui, J.-R.; Wang, R.-Q.; Tu, P.-F.; Hattori, M.; Daneshtalab, M. The cytotoxic activity of ursolic acid derivatives. Eur. J. Med. Chem. 2005, 40, 582–589. [Google Scholar] [CrossRef] [PubMed]
  17. Liu, D.; Meng, Y.-q.; Zhao, J.; Chen, L.-g. Synthesis and Anti-tumor Activity of Novel Amide Derivatives of Ursolic Acid. Chem. Res. Chin. Univ. 2008, 24, 42–46. [Google Scholar] [CrossRef]
  18. Meng, Y.-Q.; Liu, D.; Cai, L.-L.; Chen, H.; Cao, B.; Wang, Y.-Z. The synthesis of ursolic acid derivatives with cytotoxic activity and the investigation of their preliminary mechanism of action. Bioorg. Med. Chem. 2009, 17, 848–854. [Google Scholar] [CrossRef]
  19. Liu, M.-C.; Yang, S.-J.; Jin, L.-H.; Hu, D.-Y.; Xue, W.; Song, B.-A.; Yang, S. Synthesis and cytotoxicity of novel ursolic acid derivatives containing an acyl piperazine moiety. Eur. J. Med. Chem. 2012, 58, 128–135. [Google Scholar] [CrossRef]
  20. Sommerwerk, S.; Heller, L.; Kerzig, C.; Kramell, A.E.; Csuk, R. Rhodamine B conjugates of triterpenoic acids are cytotoxic mitocans even at nanomolar concentrations. Eur. J. Med. Chem. 2017, 127, 1–9. [Google Scholar] [CrossRef]
  21. Kahnt, M.; Fischer, L.; Al-Harrasi, A.; Csuk, R. Ethylenediamine Derived Carboxamides of Betulinic and Ursolic Acid as Potential Cytotoxic Agents. Molecules 2018, 23, 2558. [Google Scholar] [CrossRef] [PubMed]
  22. Kim, S.-M.; Jeong, I.H.; Yim, M.S.; Chae, M.K.; Kim, H.N.; Kim, D.K.; Kang, C.M.; Choe, Y.S.; Lee, C.; Ryu, E.K. Characterization of oleanolic acid derivative for colon cancer targeting with positron emission tomography. J. Drug Target. 2014, 22, 191–199. [Google Scholar] [CrossRef] [PubMed]
  23. Yang, X.; Li, Y.; Jiang, W.; Ou, M.; Chen, Y.; Xu, Y.; Wu, Q.; Zheng, Q.; Wu, F.; Wang, L. Synthesis and biological evaluation of novel ursolic acid derivatives as potential anticancer prodrugs. Chem. Biol. Drug Des. 2015, 86, 1397–1404. [Google Scholar] [CrossRef]
  24. Bai, K.-K.; Yu, Z.; Chen, F.-L.; Li, F.; Li, W.-Y.; Guo, Y.-H. Synthesis and evaluation of ursolic acid derivatives as potent cytotoxic agents. Bioorg. Med. Chem. Lett. 2012, 22, 2488–2493. [Google Scholar] [CrossRef] [PubMed]
  25. Rami, M.; Cecchi, A.; Montero, J.-L.; Innocenti, A.; Vullo, D.; Scozzafava, A.; Winum, J.-Y.; Supuran, C.T. Carbonic Anhydrase Inhibitors: Design of Membrane-Impermeant Copper(II) Complexes of DTPA-, DOTA-, and TETA-Tailed Sulfonamides Targeting the Tumor-Associated Transmembrane Isoform IX. ChemMedChem 2008, 3, 1780–1788. [Google Scholar] [CrossRef]
  26. Loesche, A.; Kahnt, M.; Serbian, I.; Brandt, W.; Csuk, R. Triterpene-Based Carboxamides Act as Good Inhibitors of Butyrylcholinesterase. Molecules 2019, 24, 948. [Google Scholar] [CrossRef] [PubMed]
  27. Deng, S.-L.; Baglin, I.; Nour, M.; Cavé, C. Synthesis of phosphonodipeptide conjugates of ursolic acid and their homologs. Heteroat. Chem. 2008, 19, 55–65. [Google Scholar] [CrossRef]
Sample Availability: Samples of all compounds are available from the authors.
Molecules 24 02254 g001 550
Figure 1. Structures of ursolic acid (UA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
Figure 1. Structures of ursolic acid (UA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
Molecules 24 02254 g001
Molecules 24 02254 sch001 550
Scheme 1. Synthesis of DOTA precursors 6–8: (a) NaHCO3, MeCN, 25 °C, 48 h, yield: 50% (6), 68% (7), 63% (8).
Scheme 1. Synthesis of DOTA precursors 6–8: (a) NaHCO3, MeCN, 25 °C, 48 h, yield: 50% (6), 68% (7), 63% (8).
Molecules 24 02254 sch001
Molecules 24 02254 sch002 550
Scheme 2. Synthesis of ursolic acid chelator conjugates 12–15: (a) Ac2O, CH2Cl2, NEt3, 25 °C, 2 days, 82%; (b) oxalyl chloride, CH2Cl2, DMF, 0–25 °C, 1 h, then 1-(2-Aminoethyl)piperazine, CH2Cl2, 25 °C, 2 h, yield: 82%; (c) chloroacetyl chloride, CH2Cl2, NEt3, 25 °C, 30 min, yield: 91%; (d) K2CO3, KI, 6 (for 12) or 7 (for 13) or 8 (for 14), MeCN, 25 °C, 48 h, yield: 54% (12), 82% (13), and 80% (14); (e) [(PPh3)4Pd], PPh3, pyrrolidine, MeCN, 25 °C, 3 days, yield: 96%.
Scheme 2. Synthesis of ursolic acid chelator conjugates 12–15: (a) Ac2O, CH2Cl2, NEt3, 25 °C, 2 days, 82%; (b) oxalyl chloride, CH2Cl2, DMF, 0–25 °C, 1 h, then 1-(2-Aminoethyl)piperazine, CH2Cl2, 25 °C, 2 h, yield: 82%; (c) chloroacetyl chloride, CH2Cl2, NEt3, 25 °C, 30 min, yield: 91%; (d) K2CO3, KI, 6 (for 12) or 7 (for 13) or 8 (for 14), MeCN, 25 °C, 48 h, yield: 54% (12), 82% (13), and 80% (14); (e) [(PPh3)4Pd], PPh3, pyrrolidine, MeCN, 25 °C, 3 days, yield: 96%.
Molecules 24 02254 sch002
Molecules 24 02254 sch003 550
Scheme 3. Synthesis of ursolic acid DOTA conjugates 22–27: (a) oxalyl chloride, CH2Cl2, DMF, 0–25 °C, 1 h, then amine, CH2Cl2, 25 °C, 2 h, yield: 80% (16 and 17), and 78% (18); (b) chloroacetyl chloride, CH2Cl2, NEt3, 25 °C, 0.5–4 h, yield: 94% (19), and 91% (20 and 21); (c) K2CO3, KI, 6 (for 22, 24 and 26) or 7 (for 23, 25 and 27), MeCN, 25 °C, 5 days, yield: 88% (22), 72% (23), 73% (24), 75% (25), 74% (26), and 62% (27).
Scheme 3. Synthesis of ursolic acid DOTA conjugates 22–27: (a) oxalyl chloride, CH2Cl2, DMF, 0–25 °C, 1 h, then amine, CH2Cl2, 25 °C, 2 h, yield: 80% (16 and 17), and 78% (18); (b) chloroacetyl chloride, CH2Cl2, NEt3, 25 °C, 0.5–4 h, yield: 94% (19), and 91% (20 and 21); (c) K2CO3, KI, 6 (for 22, 24 and 26) or 7 (for 23, 25 and 27), MeCN, 25 °C, 5 days, yield: 88% (22), 72% (23), 73% (24), 75% (25), 74% (26), and 62% (27).
Molecules 24 02254 sch003
Molecules 24 02254 sch004 550
Scheme 4. Synthesis of ursolic acid derivative 29: (a) KOH, MeOH, 25 °C, 48 h (for 28) or 24 h (for 29), yield: 85% (28) or 86% (29); (b) ethylene diamine, HOBt·H2O, EDC·HCl, DMF, 25 °C, 24 h, yield: 46% (c) DOTA-3T, HOBt·H2O, EDC·HCl, DMF, 25 °C, 5 days, yield: 49%.
Scheme 4. Synthesis of ursolic acid derivative 29: (a) KOH, MeOH, 25 °C, 48 h (for 28) or 24 h (for 29), yield: 85% (28) or 86% (29); (b) ethylene diamine, HOBt·H2O, EDC·HCl, DMF, 25 °C, 24 h, yield: 46% (c) DOTA-3T, HOBt·H2O, EDC·HCl, DMF, 25 °C, 5 days, yield: 49%.
Molecules 24 02254 sch004
Molecules 24 02254 g002 550
Figure 2. Comparison of synthetic routes A, B, and C for the preparation of UA-DOTA conjugate 29.
Figure 2. Comparison of synthetic routes A, B, and C for the preparation of UA-DOTA conjugate 29.
Molecules 24 02254 g002
Molecules 24 02254 g003 550
Figure 3. Extended cytotoxicity investigation after treatment of A375 cells with 24 (4.0 µM) for 24 h: (A) Fluorescence microscopic images (scale bar 20 µm), AO and PI were used; (B) Annexin V-FITC/PI assay. Examples of density plots determined by flow cytometry (Attune® Cytometric Software v 1.2.5), R1: necrotic, R2: secondary necrotic/late stage apoptotic, R3: vital, R4: apoptotic; (C) Representative examples for cell cycle evaluation via ModFit LT 5.0.
Figure 3. Extended cytotoxicity investigation after treatment of A375 cells with 24 (4.0 µM) for 24 h: (A) Fluorescence microscopic images (scale bar 20 µm), AO and PI were used; (B) Annexin V-FITC/PI assay. Examples of density plots determined by flow cytometry (Attune® Cytometric Software v 1.2.5), R1: necrotic, R2: secondary necrotic/late stage apoptotic, R3: vital, R4: apoptotic; (C) Representative examples for cell cycle evaluation via ModFit LT 5.0.
Molecules 24 02254 g003
Molecules 24 02254 g004 550
Figure 4. Extended cytotoxicity investigation after treatment of A375 cells with 22 (3.0 µM) for 48 h: (A) Fluorescence microscopic images (scale bar 20 µm), AO and PI were used; (B) Annexin V-FITC/PI assay. Examples of density plots determined by flow cytometry (Attune® Cytometric Software vl 1.2.5), R1: necrotic, R2: secondary necrotic/late stage apoptotic, R3: vital, R4: apoptotic; (C) Representative examples for cell cycle evaluation via ModFit LT 5.0.
Figure 4. Extended cytotoxicity investigation after treatment of A375 cells with 22 (3.0 µM) for 48 h: (A) Fluorescence microscopic images (scale bar 20 µm), AO and PI were used; (B) Annexin V-FITC/PI assay. Examples of density plots determined by flow cytometry (Attune® Cytometric Software vl 1.2.5), R1: necrotic, R2: secondary necrotic/late stage apoptotic, R3: vital, R4: apoptotic; (C) Representative examples for cell cycle evaluation via ModFit LT 5.0.
Molecules 24 02254 g004
Table
Table 1. Cytotoxicity of UA-DOTA conjugates (12–15, 22–27, 29), DOTA precursors (6,7), ursolic acid (UA), and doxorubicin hydrochloride (DRC): EC50 values from SRB assays after 72 h of treatment are given in µM (n.d. not detected; n.s. not soluble); the values are averaged from three independent experiments each performed in triplicate; confidence interval CI = 95%.
Table 1. Cytotoxicity of UA-DOTA conjugates (12–15, 22–27, 29), DOTA precursors (6,7), ursolic acid (UA), and doxorubicin hydrochloride (DRC): EC50 values from SRB assays after 72 h of treatment are given in µM (n.d. not detected; n.s. not soluble); the values are averaged from three independent experiments each performed in triplicate; confidence interval CI = 95%.
A375A2780HT29MCF-7FaDuNIH 3T3
UAn.d.11.7 ± 0.610.6 ± 0.712.7 ± 0.1n.d.13.1 ± 1.1
612.4 ± 2.710.5 ± 3.08.7 ± 2.711.3 ± 2.39.5 ± 0.917.3 ± 0.1
74.7 ± 0.33.8 ± 0.32.0 ± 0.24.1 ± 0.53.9 ± 0.74.5 ± 0.3
13n.d. 2.1 ± 0.44.0 ± 0.43.3 ± 0.26.0 ± 0.13.6 ± 0.5
15>60>60>60>60>60>60
221.5 ± 0.41.9 ± 0.35.7 ± 0.54.4 ± 0.73.7 ± 0.64.6 ± 1.0
242.0 ± 0.11.7 ± 0.12.3 ± 0.31.8 ± 0.12.0 ± 0.21.4 ± 0.1
292.0 ± 0.31.6 ± 0.51.7 ± 0.4n.d.2.9 ± 0.42.3 ± 0.7
12, 14, 23, 25–27n.s.n.sn.sn.s.n.s.n.s.
DRC n.d.0.01 ± 0.010.9 ± 0.21.1 ± 0.3n.d.0.06 ± 0.03
Table
Table 2. Selectivity of selected UA-DOTA conjugates (13, 22, 24, and 29), DOTA precursors (6, 7), ursolic acid (UA) and doxorubicin hydrochloride (DRC): Selectivity index (SI) is defined as: SI = EC50 (NIH 3T3)/EC50 (tumor cell line).
Table 2. Selectivity of selected UA-DOTA conjugates (13, 22, 24, and 29), DOTA precursors (6, 7), ursolic acid (UA) and doxorubicin hydrochloride (DRC): Selectivity index (SI) is defined as: SI = EC50 (NIH 3T3)/EC50 (tumor cell line).
A375A2780HT29MCF-7FaDu
UA-1.121.241.03-
61.401.651.991.531.82
70.961.182.251.101.15
13-1.710.901.090.60
223.072.420.811.051.24
240.700.820.610.780.70
291.151.441.35-0.79
DRC -6.000.070.05-

Share and Cite

MDPI and ACS Style

Kahnt, M.; Hoenke, S.; Fischer, L.; Al-Harrasi, A.; Csuk, R. Synthesis and Cytotoxicity Evaluation of DOTA-Conjugates of Ursolic Acid. Molecules 2019, 24, 2254. https://doi.org/10.3390/molecules24122254

AMA Style

Kahnt M, Hoenke S, Fischer L, Al-Harrasi A, Csuk R. Synthesis and Cytotoxicity Evaluation of DOTA-Conjugates of Ursolic Acid. Molecules. 2019; 24(12):2254. https://doi.org/10.3390/molecules24122254

Chicago/Turabian Style

Kahnt, Michael, Sophie Hoenke, Lucie Fischer, Ahmed Al-Harrasi, and René Csuk. 2019. "Synthesis and Cytotoxicity Evaluation of DOTA-Conjugates of Ursolic Acid" Molecules 24, no. 12: 2254. https://doi.org/10.3390/molecules24122254

Article Metrics

Back to TopTop